1 To address this problem,
we conducted a phase 1 and 2 trial of combined treatment with
2 We conducted a phase 1 clinical trial and treated 16 patients
3 We conducted a phase 1 dose-escalation study of daily oral ve
4 We conducted a phase 1 open-label study at ten cancer centres
5 logic mechanisms of action and supportive preclinical data,
we conducted a phase 1 trial of nivolumab combined with ipili
6 We conducted a phase 1 trial of selumetinib (AZD6244 or ARRY-
7 We conducted a phase 1 trial of the A2AR agonist regadenoson
8 We conducted a phase 1, dose-escalation, open-label trial of
9 We conducted a phase 1/1b multicenter, investigator-initiated
10 We conducted a phase 1b, multicenter, double-blind, placebo-c
11 We conducted a phase 1b-2 multicenter study to assess the saf
12 We conducted a phase 2 study of ruxolitinib in patients with
13 We conducted a phase 2 study to evaluate the clinical activit
14 We conducted a phase 2 trial in which patients with metastati
15 We conducted a phase 2 trial of 2 oral doses of solithromycin
16 We conducted a phase 2 trial of ponatinib in patients with ch
17 We conducted a phase 2, multicenter, double-blind, placebo-co
18 We conducted a phase 2, multicenter, open-label study to eval
19 We conducted a phase 2, multicenter, placebo-controlled study
20 We conducted a phase 2, open-label study at three centers in
21 To improve such patients' outcomes,
we conducted a phase 2, prospective, multicenter trial to tes
22 We conducted a phase 2, randomized, double-blind, placebo-con
23 We conducted a phase 3 open-label study to evaluate the effic
24 We conducted a phase 3 study of the efficacy and safety of th
25 We conducted a phase 3 trial of enzyme-replacement therapy in
26 We conducted a phase 3 trial to determine whether the additio
27 We conducted a phase 3 trial to evaluate the safety and effic
28 We conducted a phase 3, double-blind, placebo-controlled stud
29 We conducted a phase 3, multicenter trial comparing ATRA plus
30 We conducted a phase 3, multicenter, randomized trial of tran
31 We conducted a phase 3, nonrandomized, open-label study of th
32 We conducted a phase 3, open-label study involving both previ
33 We conducted a phase 3, open-label study involving previously
34 We conducted a phase 3, open-label trial comparing crizotinib
35 We conducted a phase 3, open-label, multicenter, noninferiori
36 We conducted a phase 3, randomized withdrawal, multicenter, p
37 We conducted a phase 3, randomized, double-blind, placebo-con
38 We conducted a phase 3, randomized, open-label study involvin
39 We conducted a phase I clinical trial of a virosomal H5N1 vac
40 We conducted a phase I clinical trial to test the safety and
41 ition and mTOR inhibition in breast and lung cancer models,
we conducted a phase I combination study of neratinib, a smal
42 We conducted a phase I dose escalation study in which 9 patie
43 We conducted a phase I dose-escalation study with (89)Zr-desf
44 We conducted a phase I study of single-agent AZD1775 in adult
45 We conducted a phase I, randomized, double-blind, placebo-con
46 We conducted a phase I/II trial to evaluate AUY922 and erloti
47 METHODOLOGY:
We conducted a Phase Ia, non-randomized clinical trial in 16
48 To explore potential mechanisms of this benefit,
we conducted a phase II study of neoadjuvant bevacizumab (sin
49 We conducted a phase IIa proof-of-concept pilot study to exam
50 We conducted a phase IIIb-IV, multicenter, randomized, double